Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

The clinical utility of estrogens for treating prostate cancer (CaP) was established in the 1940s by Huggins. The classic model of the anti-CaP activity of estrogens postulates an indirect mechanism involving the suppression of androgen production. However, clinical and preclinical studies have shown that estrogens exert growth-inhibitory effects on CaP under low-androgen conditions, suggesting additional modes whereby estrogens affect CaP cells and/or the microenvironment. Here we have investigated the activity of 17beta estradiol (E2) against androgen-independent CaP and identified molecular alterations in tumors exposed to E2. E2 treatment inhibited the growth of all four androgen-independent CaP xenografts studied (LuCaP 35V, LuCaP 23.1AI, LuCaP 49, and LuCaP 58) in castrated male mice. The molecular basis of growth suppression was studied by cDNA microarray analysis, which indicated that multiple pathways are altered by E2 treatment. Of particular interest are changes in transcripts encoding proteins that mediate immune responses and regulate androgen receptor signaling. In conclusion, our data show that estrogens have powerful inhibitory effects on CaP in vivo in androgen-depleted environments and suggest novel mechanisms of estrogen-mediated antitumor activity. These results indicate that incorporating estrogens into CaP treatment protocols could enhance therapeutic efficacy even in cases of advanced disease.

[1]  M. Gross,et al.  Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial , 2006, BJU international.

[2]  P. Nelson,et al.  Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells , 2005, The Prostate.

[3]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Robert Clarke,et al.  Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. , 2005, Carcinogenesis.

[5]  K. Saoo,et al.  Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. , 2005, Carcinogenesis.

[6]  Ruth Etzioni,et al.  Metastases of prostate cancer express estrogen receptor-beta. , 2004, Urology.

[7]  I. Leav,et al.  Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. , 2004, The American journal of pathology.

[8]  S. Ho,et al.  The novel estrogen 17alpha-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro. , 2004, Molecular cancer therapeutics.

[9]  R. Vessella,et al.  Prostate cancer expression of runt‐domain transcription factor Runx2, a key regulator of osteoblast differentiation and function , 2003, The Prostate.

[10]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[11]  K. Hunt,et al.  P202, an interferon-inducible protein, inhibits E2F1-mediated apoptosis in prostate cancer cells. , 2003, Biochemical and biophysical research communications.

[12]  P. Nelson,et al.  Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. , 2002, Journal of the National Cancer Institute.

[13]  M. Naoe,et al.  Correlation between major histocompatibility complex class I molecules and CD8+ T lymphocytes in prostate, and quantification of CD8 and interferon‐γ mRNA in prostate tissue specimens , 2002, BJU international.

[14]  Seong-Jin Kim,et al.  Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. , 2002, Cancer research.

[15]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Nelson,et al.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. , 2002, The American journal of pathology.

[17]  B. Higgins,et al.  Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.

[18]  Seong-Jin Kim,et al.  Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. , 2002, Cancer research.

[19]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[20]  Robert Tibshirani,et al.  Transcriptional programs activated by exposure of human prostate cancer cells to androgen , 2002, Genome Biology.

[21]  M. Naoe,et al.  [MHC-class I expression on prostate carcinoma and modulation by IFN-gamma]. , 2002, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[22]  A. Feldman,et al.  Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts , 2002, International journal of cancer.

[23]  R. Vessella,et al.  Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  D. Rutledge,et al.  Osteoporosis in men treated with androgen suppression therapy for prostate cancer. , 2002, Clinical journal of oncology nursing.

[25]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[26]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[27]  Y. Ouchi,et al.  Differential Expression of Estrogen Receptor β (ERβ) and Its C-Terminal Truncated Splice Variant ERβcx as Prognostic Predictors in Human Prostatic Cancer , 2001 .

[28]  M. Hung,et al.  p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. , 2001, Cancer Research.

[29]  J. Gustafsson,et al.  Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer , 2001 .

[30]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[31]  R. Franco,et al.  Estrogen receptor β expression in human prostate tissue , 2001, Molecular and Cellular Endocrinology.

[32]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[33]  H. Johnson,et al.  Down-Regulation of neu/HER-2 by Interferon-γ in Prostate Cancer Cells , 2000 .

[34]  P. Subramaniam,et al.  Inhibition of the Glioblastoma Cell Cycle by Type I IFNs Occurs at Both the G1 and S phases and Correlates With the Upregulation of P21WAF1/CIP1 , 2000, Journal of Neuro-Oncology.

[35]  S. Ho,et al.  Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. , 2000, Cancer research.

[36]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[37]  N. Bander,et al.  MHC class I and II expression in prostate carcinoma and modulation by interferon‐alpha and ‐gamma , 1997, The Prostate.

[38]  E. Borden,et al.  Tamoxifen enhances interferon-regulated gene expression in breast cancer cells , 1997, Molecular and Cellular Biochemistry.

[39]  R L Vessella,et al.  Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration , 1996, International journal of cancer.

[40]  R L Vessella,et al.  Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  A. Belldegrun,et al.  In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines , 1996, Cancer.

[42]  Presti Jc.  Estrogen therapy for prostate carcinoma. , 1996 .

[43]  E. Crawford,et al.  Estrogens in the treatment of prostate cancer. , 1995, The Journal of urology.

[44]  N. Bashirelahi,et al.  Androgen, estrogen, and progesterone receptors in normal and aging prostates , 1995, Microscopy research and technique.

[45]  G. Carruba,et al.  Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. , 1994, Cancer research.

[46]  C. Cordon-Cardo,et al.  Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. , 1991, Cancer research.

[47]  K. Pantel,et al.  Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. , 1991, Cancer research.

[48]  D. Byar,et al.  Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. , 1989, NCI monographs : a publication of the National Cancer Institute.

[49]  D. Wolgemuth,et al.  Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland. , 1988, Molecular endocrinology.

[50]  G. Hutchins,et al.  Metastatic behavior of prostate cancer: Cluster analysis of patterns with respect to estrogen treatment , 1986, Cancer.

[51]  D. Byar,et al.  Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo , 1970, Cancer.

[52]  H. Brendler.  Therapy with orchiectomy or estrogens or both. , 1969, JAMA.

[53]  H. Burger,et al.  Carcinoma of prostate: response of plasma luteinizing hormone and testosterone to oestrogen therapy. , 1968, British medical journal.

[54]  J. Bailar,et al.  Carcinoma of the Prostate: Treatment Comparisons , 1967 .

[55]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[56]  R. Vessella,et al.  Xenograft Models of Human Prostate Cancer , 2007 .

[57]  Cherrier Mm.  Androgens and cognitive function. , 2005 .

[58]  Y. Miyachi,et al.  The changes in the binding capacity of testosterone-oestradiol binding globulin (TeBG) following castration and DES-D administration in patients with prostatic carcinoma , 2004, Urological Research.

[59]  R. Vessella,et al.  Expressionof Runt-Domain Transcription FactorRunx 2 , aKeyRegulatorof OsteoblastDifferentiation and Function , 2003 .

[60]  Colin C. Pritchard,et al.  The human (PEDB) and mouse (mPEDB) Prostate Expression Databases , 2002, Nucleic Acids Res..

[61]  J. Dwyer,et al.  Evaluation of the effects of 17beta-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. , 2002, Endocrinology.

[62]  G. Romeo,et al.  IRF-1 as a negative regulator of cell proliferation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[63]  J. Dwyer,et al.  Evaluation of the Effects of 17β-Estradiol (17β-E2) on Gene Expression in Experimental Autoimmune Encephalomyelitis Using DNA Microarray. , 2002, Endocrinology.

[64]  R. Franco,et al.  Estrogen receptor beta expression in human prostate tissue. , 2001, Molecular and cellular endocrinology.

[65]  I. Leav,et al.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. , 2001, The American journal of pathology.

[66]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[67]  Y. Ouchi,et al.  Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. , 2001, Biochemical and biophysical research communications.

[68]  J. Gustafsson,et al.  Frequent loss of estrogen receptor-beta expression in prostate cancer. , 2001, Cancer research.

[69]  P. Abel,et al.  Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases. , 2000, The Journal of pathology.

[70]  H. Johnson,et al.  Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. , 2000, Cancer research.

[71]  Todd Smith,et al.  The Prostate Expression Database (PEDB): status and enhancements in 2000 , 2000, Nucleic Acids Res..

[72]  Todd Smith,et al.  PEDB: the Prostate Expression Database , 1999, Nucleic Acids Res..

[73]  K. Griffiths.  12 Evaluation of the different endocrine approaches in the treatment of prostatic carcinoma , 1987 .

[74]  Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. , 1967, Surgery, gynecology & obstetrics.